Cryo-HITTM Cryosurgery System is a medical device for minimally invasive ultra-low temperature freezing and ablation of tumors. It is the crystallization of aerospace guidance technology, which is the cold isolation technology of argon gas applied to the medical field. Cryo-HITTM Cryosurgery System is a product manufactured by Galileo Israel. Galileo Israel is the world leader in cryotherapy equipment market, R & D headquarters is located in YOKNEAM, Israel, Galileo Cryo-HITTM brand is the first brand in Europe and the United States market, the product is currently retained more than 400 units worldwide, with 33 patented technology. äCryo-HITTM cryosurgery system was registered and approved by the Ministry of Health, Health Technology and Structures Authority, and the Ministry of Medical Devices of the State of Israel in 1997; passed the CE registration of the European Community in 1999; and passed the registration of the U.S. FDA in 2000, and is the only system in the world that is approved by the FDA for the treatment of benign diseases of the liver, lungs, breasts, uterus, kidneys, prostate, nerves (including neuralgia), and bones. It is the only FDA-approved device for the cryoablation of benign and malignant tumors of liver, lung, breast, uterus, kidney, prostate, nerves (including nerve pain relief), and bones, etc. In May 2003, it entered the Chinese market with the approval of the SFDA registration of the State Food and Drug Administration of the People’s Republic of China and was approved to be used in the cryosurgical treatments for the oncology, general surgery, thoracic surgery, dermatology, otolaryngology, obstetrics and gynecology, anorectal medicine, urology, and neurology (including nerve pain relief) departments. Cryo-Hit Cryosurgery System”, the registration number of which is GuoDaoGuanMechanism(Jin)Zi 2003 No.3580683.ä CryoHit Cryosurgery System is registered as “Cryo-Hit” by SFDA, and is registered as “Cryo-Hit” by Israel, and is registered as “Cryo-Hit” by the European Community, and is registered as “Cryo-Hit” by the U.S. FDA. Targeted therapy technology – U.S. argon-helium cryo-knife is the world’s only high-tech medical system that simultaneously combines the multiple efficacies of ultra-low-temperature freezing at -150 degrees Celsius, interventional hyperthermia, 200 degrees Celsius temperature reversal and immune enhancement, etc. It is superior to pure hyperthermia or pure cryo-surgery. It is superior to pure hyperthermia or pure cryotherapy. It can kill cancer cells more thoroughly and effectively. Synchronized with the world level of tumor treatment, we introduced the U.S. argon-helium ultra-cold knife tumor treatment technology system in 2002, which is a pure physical treatment with precise effect of completely destroying the tumor (more than 95% of the effective rate), the treatment doesn’t lead to the proliferation of the cancer cells, the treatment is minimally invasive and painless, the recovery is fast, it doesn’t damage the normal tissues, and the argon-helium ultra-cold knife treatment, which is different from the radiotherapy, doesn’t have any poisonous side effect, and it can also effectively It can also effectively regulate the secretion of cytokines and antibodies, and after this method of treatment, the immune function of the patient’s body is significantly improved compared with that before treatment, and the long-term survival rate is significantly improved, in addition to the advantages of low treatment cost and short hospitalization time. It is a high-tech tumor treatment developed after radiofrequency ablation therapy, microwave, laser, ultrasonic aggregation knife, gamma knife and so on. It has significant advantages in the treatment of lung cancer, liver cancer, breast cancer, kidney tumor and other solid tumors. It represents the most advanced level of tumor treatment in the world. The standardized treatment procedure of this new technology has provided the best choice for tumor patients. It has improved the comprehensive treatment effect of middle and late-stage tumors has been clinically affirmed. Clinical statistics show that the effective rate of argon-helium supercooled knife in the treatment of middle and late stage lung cancer reaches 96.5% (while the effective rate of chemotherapy and other drug treatments is 20-30%). The technology is applicable to lung cancer treatment, benign lung tumors, liver cancer treatment, hepatic hemangioma, pancreatic cancer, breast cancer, breast hyperplasia, brain tumor, spinal meningioma, prostate cancer, prostate hyperplasia, renal cancer, adrenal tumor, perineal tumor, uterine cancer, cervical cancer, ovarian cancer, penile cancer, skin cancer, melanoma, hemangioma, osteosarcoma, tonsil cancer, pharyngeal tumor, nasopharyngeal cancer, neurofibroma, liposarcoma, oral cancer, tongue cancer, maxillofacial tumor, neck tumor, etc. Ar-He ultracold knife is suitable for the treatment of early, middle and late solid tumors, especially for those middle and late-stage patients who cannot be surgically resected, or those who are unwilling to be operated for various reasons such as old age and physical weakness, and so on; it is the first choice for patients who are unwilling to bear the side-effects of radiotherapy or those who have poor therapeutic effect of radiotherapy or interventional therapy; and it is the first choice for patients with recurrent and metastatic middle and late-stage tumors. In order to better use the technology to relieve patients’ pain and improve the comprehensive treatment effect, the Center has concentrated the powerful expert team strength of thoracic surgery, liver disease research center, hepatobiliary surgery, oncology, brain surgery, urology, CT, B ultrasound, intervention and other departments, and has successfully cured or effectively prolonged hundreds of cases of tumors that cannot be treated with radiotherapy or chemotherapy or interventional therapy. or effectively prolonged the lives of hundreds of patients with inoperable middle and late-stage malignant tumors, alleviated patients’ pain, improved the quality of life, and made breakthrough progress. Temperature sensor is included in the probe above 2mm, which can monitor the temperature in the center of the frozen area. 1.47mm probe does not have a temperature sensor, if you need to monitor the temperature, you can insert the temperature probe separately to monitor the temperature in the tissue. The monitored temperature change and freezing time can be displayed as a temperature and time curve on the liquid crystal display, so that the operator can understand the freezing process in time. Most of the surgery is mainly with local anesthesia, and the treatment is usually performed under ultrasound, CT, MRI guided puncture, and the whole process of puncture is monitored in real time. Surgical modalities include percutaneous puncture, puncture under direct surgical visualization, and puncture under cavitation. The argon knife is accurately punctured into the tumor body under CT or B ultrasound positioning guidance, and then the argon gas is firstly activated, which can be籍 argon gas in the tip of the knife rapid expansion to produce the refrigeration effect, and the lesion tissue will be frozen to minus 140℃~170℃ within 15 seconds. After 15~20 minutes, turn off the argon, and then start the helium, and helium in the tip of the rapid expansion, rapid heating in the ultra-low temperature state of the diseased tissue, can make the temperature of the diseased tissue from -140 ℃ rose to zero 20 ℃ ~ 40 ℃ so as to carry out rapid thermal therapy. It lasts for 3~5 minutes and then repeat the treatment once more. This kind of heat and cold reversal therapy is particularly thorough in destroying the diseased tissue. The speed, time and temperature of cooling and heating, and the size and shape of the destroyed area can be monitored in real time by ultrasound or CT and precisely set and controlled by computer. More importantly, because the Ar-He knife cooling or heating is limited to the tip of the knife, the shaft does not cause hot or cold damage to the tissues in the path of the puncture. The Ar-He knife is currently the only instrument available for minimally invasive percutaneous cryotherapy. Ar-He knife cryotherapy can be used as an alternative treatment to surgery for small tumors in early stages. For larger tumors in advanced stages, cryotherapy can be used as a palliative treatment to enhance the effect of comprehensive treatment, which can reduce the tumor load, alleviate the symptoms, improve the quality of life and prolong the survival time. Cryo-HITTM cryosurgery system has a wide range of indications for the treatment of tumors, and is mainly applied to various solid tumors in the whole body. It includes liver cancer, lung cancer, prostate cancer, kidney cancer, pancreatic cancer, benign and malignant tumors of bones, adrenal cancer, meningioma, glioma, uterine fibroids, uterine cancer, ovarian cancer, breast cancer, breast fibroids, as well as used for pain relief of cancers, and so on, and at present, it is most commonly used for liver and lung cancers. Indications for selecting Ar-He knife cryotherapy: ・Preferred by patients who are unable or unwilling to undergo surgery, patients who are unwilling to undergo radiotherapy or those who have poor results of radiotherapy, and patients with recurrence, metastasis, and other middle and advanced stages of the disease. ・Professor of Alkney General Hospital, an international tumor authority in the U.S., said frankly: Ultra-low temperature therapy is so effective that it will start to be the first choice for cancer treatment in a few years. Professor Kay of American Denex Hospital said, “This therapy is not as traumatic to human body as other therapies, the patient’s hospitalization time is short, and it can exactly kill the cancer cells, which is the ideal choice for tumor patients.” ・Since 1999, when China’s State Administration of Medicine approved Ar-He Supercooling Knife to enter China, China’s famous Academician Wu Mengchao, Academician Tang Zhaoyou, Academician Hao Xishan, and other experts in China have successively applied this technology to more than 20,000 cases of middle- and late-stage liver cancer, lung cancer, breast cancer, pancreatic cancer, brain tumors, prostate cancer, and renal tumors, etc, and have achieved remarkable results. In 2000, in view of the good efficacy and superior safety of argon-helium supercooled knife treatment of tumors, the United States will be the argon-helium supercooled knife treatment of solid tumors into the universal health care plan, the European medical insurance companies for argon-helium supercooled knife treatment to provide insurance. Now more than 360 hospitals in the United States have been equipped with argon helium ultracold knife. Since July 2002, the Federation of Physicians of 35 states in the U.S. has designated Ar-He ultracold knife as the first choice for the treatment of prostate cancer (the incidence of prostate cancer in the U.S. ranked first), and in 2003, the World Congress on Targeted Oncology recommended that the first choice for middle and advanced lung cancer and liver cancer is Ar-He ultracold knife. What are the advantages and disadvantages of Ar-He knife treatment? A: Ar-He knife is a minimally invasive treatment with less bleeding. 5cm lesions are generally frozen with a diameter of 7cm, which can basically achieve the effect of surgical resection, but for larger and irregular lesions, the effect of “cold cutting” is not as thorough as that of surgery. Therefore, if you can operate or do surgery. If you do not have the conditions for surgical excision, argon helium knife has unique features. First of all, its curative effect is exact, and the tumor will die wherever it is frozen. Secondly, it is a physical treatment without any side effects. Secondly, it is a physical treatment without any side effects. Then, it has a short treatment period, which can be finished in one treatment, and can be discharged from the hospital after 2-3 days of observation, so the non-therapeutic expenditure is less. The argon helium knife is not really a scalpel, but just a hollow stainless steel needle. However, this small steel needle can save some advanced cancer patients who have been sentenced to “death”, especially those who have failed radiotherapy, lost the opportunity for surgery or are unwilling to undergo surgery, can be treated with Ar-He knife. The essence of “Ar-He knife” is freezing + thermotherapy treatment of tumors, when argon is released rapidly in the tip of the needle, can be frozen in more than ten seconds to -120 ℃ ~ -165 ℃; when helium is released rapidly in the tip of the needle, will produce rapid rewarming and warming, rapid thawing of the ice ball, eliminating tumors. Moreover, the speed and time of cooling and warming, as well as the size and shape of the ice ball, can be precisely set and controlled. In addition, the method can rapidly reduce the tumor load, and the load can be reduced by more than 95% for tumors with a diameter of less than 4 cm, and more than 80% for tumors with a diameter of more than 5 cm, and smaller tumors can be radically cured, prolonging the patient’s survival period. Moreover, Ar-He knife does not have the side effects of chemotherapy and radiotherapy, and can be used in the treatment of lung cancer, liver cancer, prostate cancer, kidney cancer, breast cancer and so on. At present, this technology has been popularized and used in 50 hospitals. As this technology only freezes and heats the tip of the knife to treat tumors, it causes less damage to patients, less bleeding, fewer complications, faster recovery, repeatable treatment, and can be combined with chemotherapy, radiotherapy or surgery. Ar-He Supercooling Knife Treatment Scope The effect of malignant solid tumors is the best. It includes: liver cancer, lung cancer, brain tumor, breast cancer, pancreatic cancer, thyroid cancer, prostate cancer, kidney and adrenal tumors, abdominal and pelvic tumors, bone tumors, soft tissue tumors, head and neck and skin tumors, metastatic gastrointestinal tumors, and other solid tumors Benign tumors and benign proliferative lesions Prostatic hyperplasia, benign breast tumors, hemangiomas, uterine fibroids, cysts, warts, hemorrhoids, and recurrent pre-cancerous lesions, Oral leukoplakia, etc. Ar-He knife technology has better effect on early stage tumors that can be completely removed through surgical treatment. Tumors in the middle and late stages are not only confined to the local fluid, but have already metastasized to other parts, such as lymph nodes, blood and other organs. It is hard to achieve complete cure for such a tumor. However, through argon helium knife treatment, we can allow patients to “coexist” with their tumors, alleviate their pain and improve their quality of life. New Breakthrough in Tumor Treatment The characteristic of Ar-He knife is that it can reduce the temperature to a very low level, and it is a purely physical method. It can lower the temperature to about 150 degrees below zero in less than a minute, and it can also quickly rewarm the temperature after freezing, such as raising the temperature to 20-30 degrees above zero in less than a minute, and the temperature difference can reach about 180 degrees. Just like when we take frozen meat out of the freezer and quickly put it into hot water, we see the surface of the meat whitening, indicating that the tissue is denaturing and the cells are starting to die. As I mentioned earlier, tumors are caused by excessive proliferation of out-of-control cells, and by freezing the local cells in cryotherapy, we expand them to the surrounding area through the cytosol and intercellular bridges, just like dominoes, covering the local fluid, so that the tumor cells can die quickly. Cooperation of treatment There are two issues involved in the treatment process, the first one is how we can treat the tumor site more precisely. It’s like a GPS device commonly used in automobiles, so we can know exactly where we’ve been. We have to do it under CT or ultrasound guidance, and it can be monitored in real time. The location of the tumor is determined by imaging, and the device intervenes the argon helium knife into the fluid where the tumor is located under CT guidance, and after that it’s designed according to the size of the fluid, such as sometimes one knife, sometimes multiple knives. We cover the area as quickly and comprehensively as possible depending on the size of the tumor, and this is the real-time guidance of the argon helium knife. The second issue is real-time monitoring, for example, what degree of tumor treatment, when we terminate the treatment, when to strengthen the treatment, we can understand the scope of treatment according to the real-time monitoring image on the timely adjustment of the treatment time and the number of treatment knives. Indications of Ar-He ultracold knife treatment for lung cancer Peripheral lung cancer that cannot tolerate surgical resection Primary lung cancer that cannot be resected by surgical exploration (intraoperative combined treatment) Central lung cancer that involves lobar bronchioles Central lung cancer that is partially close to the hilar area More limited metastatic lung cancer Partial research results of Ar-He ultracold knife treatment for lung cancer One-year survival rate of ar-helium ultracold knife cryotherapy in middle and advanced lung cancer (inoperative patients) 81.67% (for early lung cancer, the survival rate of surgery is 76%). The effective rate of argon-helium ultracold knife cryotherapy for advanced lung cancer was 69.6%, complete remission rate was 8.7%, one-year survival rate was 69.2%, and two-year survival rate was 53.7%. Conclusion: Ar-He ultracold knife treatment of lung cancer is similar to palliative surgical resection, and trauma is small, reaction is light, postoperative mental and physical recovery is fast, and there is no obvious pain, so it is feasible for Ar-He ultracold knife treatment of locally advanced lung tumors, and the combination of Ar-He ultracold knife and radiotherapy can treat locally advanced lung tumors thoroughly, and the efficacy of the treatment is safe and reliable. Comparison of Ar-He-ULT targeted therapy combined with chemotherapy in treating lung cancer and chemotherapy alone, conclusion: the rate of complete remission and partial remission of tumors in Ar-He-ULT combined with chemotherapy is 100%, while the rate of complete remission and partial remission of tumors in chemotherapy alone is 53%. Comparison of argon-helium supercooled knife with radiofrequency ablation therapy, ultrasound focused knife, gamma knife, X-knife and so on.